습성 연령관련황반변성(습성 AMD) - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• In 2023, the market size of Wet Age-Related Macular Degeneration (Wet AMD) was highest in the US among the 7MM, accounting for approximately USD 2,599 million which is further expected to rise by 2036.
• According to DelveInsight estimate, in 2025, the total prevalent cases of AMD were nearly 72 million in the 7MM.
• Various therapies are employed to treat Wet Age-Related Macular Degeneration (Wet AMD), currently approved therapies includes EYLEA (aflibercept), LUCENTIS (ranibizumab), BEOVU (brolucizumab), AVASTIN (bevacizumab), and Others. Among these, EYLEA had the highest market share in 2023, accounting for approximately USD 4,276 million in the 7MM, according to our analysis.
• The market is driven by the aging population, innovative therapies, and increased screening, while high costs, limited access, and treatment burden are key barriers. Reimbursement varies, with growing emphasis on value-based models. Unmet needs include longer-acting therapies, improved efficacy, and better early detection methods.
• The market size of Wet Age-Related Macular Degeneration (Wet AMD) in Japan was USD 1,163 million in 2023, which is expected to rise by 2036.

DelveInsight's "Wet Age-Related Macular Degeneration (Wet AMD) - Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration (Wet AMD), historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration (Wet AMD) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

The Wet Age-Related Macular Degeneration (Wet AMD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Wet Age-Related Macular Degeneration (Wet AMD) market size from 2022 to 2036. The Report also covers current Wet Age-Related Macular Degeneration (Wet AMD) treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2022-2036

Key Factors Driving the Growth of the Wet AMD Market

• Rising Aging Population and Disease Prevalence: The most significant driver of the Wet AMD market is the rapidly expanding geriatric population. Since Wet AMD primarily affects individuals aged 60 years and above, the global increase in life expectancy is directly contributing to a larger patient pool.

Advancements in Diagnostic Technologies: Technological innovations such as optical coherence tomography (OCT), fundus imaging, and AI-based diagnostic tools have significantly enhanced early detection and disease monitoring.

• Emerging Gene and Stem Cell Therapies Redefining Wet AMD Management: Emerging gene and stem cell therapies (e.g., RGX-314, Ixo-vec) offer durable, potentially one-time treatments for wet AMD, reducing injection burden and transforming long-term disease management.
• Strong Pipeline and Advancements in Therapeutics: The competitive wet AMD clinical trial landscape is crowded with several emerging therapies such as Ixoberogene soroparvovec (Ixo-vec) (Adverum Biotechnologies), Surabgene lomparvovec (RGX-314) (Regenxbio/AbbVie), OGX-110 (Ocugenix), AKST4290 (Alkahest), RBM-007 (Ribomic USA), 4D 150 (4D Molecular Therapeutics), AM712 (AffaMed Therapeutics), CLS-AX (axitinib) (Clearside Biomedical), CG-P5 peptide (Caregen), NG101 (Elisigen), NT-101 (NexThera), Migaldendranib (MGB) (Ashvattha Therapeutics), ABI-110 (Avirmax Biopharma), and others in different stages of development.

Wet Age-Related Macular Degeneration Treatment Market

Wet Age-Related Macular Degeneration (Wet AMD) Overview

Wet Age-Related Macular Degeneration (Wet AMD) is a chronic eye disorder that results from the abnormal growth of blood vessels beneath the macula, a small area of the retina responsible for central vision. These vessels leak blood and fluid, causing rapid and severe vision loss. The main risk factors include age, genetic predisposition, and lifestyle factors like smoking. Wet AMD is typically more severe than its counterpart, dry AMD, and can lead to permanent central vision impairment.

Wet Age-Related Macular Degeneration (Wet AMD) Diagnosis

Diagnosing wet age-related macular degeneration (AMD) involves several steps. Initial evaluation includes a comprehensive eye exam with dilated fundus photography to visualize the retina and macula. Optical coherence tomography (OCT) is essential for identifying fluid or blood under the retina, indicative of wet AMD. Fluorescein angiography may also be used to detect leaking blood vessels in the macula. Symptoms prompting diagnosis typically include blurred vision, dark spots, or distorted lines in the central vision. Early detection is critical, as prompt treatment can slow disease progression and preserve vision. Patients with wet AMD require ongoing monitoring and care.

Wet Age-Related Macular Degeneration (Wet AMD) Treatment

Treatment for Wet-Age Related Macular Degeneration (Wet-AMD) primarily focuses on halting disease progression and preserving vision. The standard treatment involves the use of anti-VEGF (vascular endothelial growth factor) drugs such as Ranibizumab (Lucentis), Aflibercept (Eylea), and Brolucizumab (Beovu). These are administered via intravitreal injections to reduce new blood vessel growth and fluid leakage in the retina. Some patients may benefit from photodynamic therapy (PDT), which uses light-activated drugs to destroy abnormal blood vessels. Advances in gene therapy and implantable devices are also under investigation to provide longer-lasting treatment solutions and improve patient outcomes.

Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology

As the market is derived using a patient-based model, the Wet Age-Related Macular Degeneration (Wet AMD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Prevalent Cases Of Age-Related Macular Degeneration (AMD), Diagnosed Prevalent Cases Of Age-Related Macular Degeneration (AMD), Type-Specific Diagnosed Prevalent Cases Of Age-Related Macular Degeneration (AMD), and Total Age-Specific Cases Of Wet-AMD in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2022 to 2036.

• According to DelveInsight estimate, in 2025, the total prevalent cases of AMD were nearly 72 million in the 7MM.
• The US accounted for the second highest number of diagnosed prevalent cases of wet-AMD with approximately 26% of total diagnosed prevalent cases of 7MM.
• In the US, the total age-specific cases of wet AMD were approximately 99,800, 425,500, and 493,500 in the <=64 years, 65 ̶ 84 years, and 85+ years of age groups, respectively, in 2025.
• Among EU4 and the UK, France accounted the highest number of diagnosed prevalent cases of wet-AMD, while the UK accounted the least number of cases in 2025.

Wet Age-Related Macular Degeneration (Wet AMD) Recent Developments

• In March 2026, Outlook Therapeutics provided an update following its recent Type A meeting with the US Food and Drug Administration (FDA) to discuss a Complete Response Letter (CRL) for the Biologics License Application (BLA) for bevacizumab (LYTENAVA) for the treatment of wet-AMD.
• In December 2025, Outlook Therapeutics announced that the US FDA issued a CRL declining to approve bevacizumab (LYTENAVA) for the treatment of wet-AMD.
• In October 2025, Regenxbio announced the completion of Phase II pivotal trials (ATMOSPHERE and ASCENT) evaluating surabgene lomparvovec (RGX-314) for the treatment of wet-AMD, with topline data expected in 2026.
• In September 2025, Roche presented new data from the AVONELLE-X and SALWEEN studies of VABYSMO at the 25th Euretina Congress. Findings from the open-label AVONELLE-X study highlight VABYSMO's sustained efficacy, safety, and durability over four years in patients with wet-AMD.
• In September 2025, Adverum Biotechnologies announced that screening for the ARTEMIS, its first pivotal Phase III trial evaluating Ixo-vec in wet AMD, is expected to be completed by September 30, and data readout in 1Q 2027.

Wet Age-Related Macular Degeneration (Wet AMD) Drug Chapters

The drug chapter segment of the Wet Age-Related Macular Degeneration (Wet AMD) report encloses a detailed analysis of Wet Age-Related Macular Degeneration (Wet AMD) off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Wet Age-Related Macular Degeneration (Wet AMD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Wet Age-Related Macular Degeneration Marketed Drugs

BEOVU (Brolucizumab): Novartis

BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules.

EYLEA (aflibercept): Regeneron Pharmaceuticals

EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials.

EYLEA (aflibercept) received FDA approval in November 2011 for treating wet-AMD with a dosage of 2 mg every 4 weeks for the first 12 weeks, then every 8 weeks. It was approved by the European Commission in November 2012 and by Japan's MHLW in September 2012 for the same condition.

VABYSMO (faricimab): Roche/ Genentech, Inc.

VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels.

VABYSMO is now approved in the European Union and nine other countries around the world, including the US, Japan, and the UK, for people living with "wet" age-related macular degeneration and diabetic macular edema.

Wet Age-Related Macular Degeneration Emerging Drugs

Ixoberogene soroparvovec (Ixo-vec): Adverum Biotechnologies

Ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) is Adverum's clinical-stage gene therapy product candidate being developed for the treatment of wet-AMD. Ixo-vec utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. It is believed that ADVM-022 has the potential to provide a durable, safe and cost-effective in-office treatment option that addresses the needs of the patients, and their families, as well as retina specialists and health systems worldwide. The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for Ixo-vec for the treatment of wet-AMD. Ixo-vec has also received PRIME designation from the EMA and the Innovation Passport from the United Kingdom's Medicines and Healthcare Products Regulatory Agency for the treatment of wet-AMD. Currently, the drug is being investigated in Phase III.

Surabgene lomparvovec (RGX-314): Regenxbio/AbbVie

RGX-314 is being developed as a novel, one-time sub retinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize VEGF activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. It is a potential one-time gene therapy for the treatment of wet-AMD, diabetic retinopathy, and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet-AMD in Phase III and II/III clinical trials. The company anticipates submitting global regulatory applications in the first half of 2026.

OGX-110: Ocugenix

OGX-110 is a novel small molecule therapy in development for wet-AMD, designed to target both abnormal blood vessels and fibrosis, key drivers of disease progression and irreversible blindness. OGX-110 selectively activates the CXCR3 pathway, a natural wound-healing mechanism in the retina, which noncompetitively overrides pro-angiogenic and pro-fibrotic signals (including VEGF), leading to the regression of pathological neovascularization and fibrotic tissue rather than simply controlling edema. As per company's pipeline, the drug is currently active in Phase I clinical trial for wet-AMD.

Wet Age-Related Macular Degeneration (Wet AMD) Market Outlook

Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients.

Another treatment option is photodynamic therapy (PDT), which involves intravenous administration of a light-sensitive drug, verteporfin (Visudyne), followed by the application of a low-level laser to the eye. PDT targets and destroys the abnormal blood vessels without causing significant damage to the surrounding retina. However, its use has declined with the advent of more effective anti-VEGF therapies.

In some cases, thermal laser photocoagulation might be employed to directly destroy the abnormal blood vessels, though this method is less common due to its potential to cause scarring and vision loss. Additionally, recent advancements include the development of sustained-release anti-VEGF delivery systems, such as port delivery systems, which aim to reduce the frequency of injections.

Overall, the choice of treatment depends on the specific characteristics of the AMD and the patient's response to initial therapies. Regular monitoring and individualized treatment plans are crucial to achieving the best outcomes and preserving vision for patients with wet AMD.

• The market size of Wet Age-Related Macular Degeneration (Wet AMD) in the 7MM was nearly USD 7,783 million in 2023, which is further anticipated to increase during the forecast period.
• The United States accounted for the highest market size of Wet Age-Related Macular Degeneration (Wet AMD) approximately 33% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
• Among the EU countries, Germany had the highest market size with nearly USD 1,313 million each in 2023, while Spain had the lowest market size for Wet Age-Related Macular Degeneration (Wet AMD) with USD ~ 353 million in 2023.
• With the expected launch of upcoming therapies, such as OPT-302, KSI-501, and RGX-314, among others, the total market size of Wet Age-Related Macular Degeneration (Wet AMD) is expected to show change in the upcoming years.

Wet Age-Related Macular Degeneration (Wet AMD) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2022-2036. For example, RGX-314 in the US is expected to be launched by 2026 with a peak share of 0.5%. RGX-314 is anticipated to take 6 years to peak with a medium uptake.

Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Development Activities

The report provides insights into different Wet Age-Related Macular Degeneration clinical trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Wet Age-Related Macular Degeneration (Wet AMD) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Wet Age-Related Macular Degeneration (Wet AMD) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Cleveland Clinic - Cole Eye Institute, Cleveland, US; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, US; Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami; Thomas Jefferson University, US; University of Louisville School of Medicine, Louisville, US; Department of Ophthalmology, University of Bonn, Germany; Department of Experimental Medicine, University Tor Vergata, Viale Oxford, Rome, Italy; Department of Ophthalmology, Kansai Medical University, Hirakata, Osaka, Japan; and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Wet Age-Related Macular Degeneration (Wet AMD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Wet Age-Related Macular Degeneration Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of Wet Age-Related Macular Degeneration (Wet AMD), explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Wet Age-Related Macular Degeneration (Wet AMD) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Wet Age-Related Macular Degeneration (Wet AMD) market.

Wet Age-Related Macular Degeneration (Wet AMD) Report Insights

• Wet Age-Related Macular Degeneration Patient Population
• Wet Age-Related Macular Degeneration Therapeutic Approaches
• Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Analysis
• Wet Age-Related Macular Degeneration (Wet AMD) Market Size and Trends
• Existing and Future Market Opportunity

Wet Age-Related Macular Degeneration (Wet AMD) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Wet Age-Related Macular Degeneration Drugs Uptake
• Key Wet Age-Related Macular Degeneration Market Forecast Assumptions

Wet Age-Related Macular Degeneration (Wet AMD) Report Assessment

• Current Wet Age-Related Macular Degeneration Treatment Practices
• Wet Age-Related Macular Degeneration Unmet Needs
• Wet Age-Related Macular Degeneration Pipeline Product Profiles
• Wet Age-Related Macular Degeneration Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Wet Age-Related Macular Degeneration Market Drivers
• Wet Age-Related Macular Degeneration Market Barriers

Key Questions:

• Wet Age-Related Macular Degeneration Market Insights
• What was the Wet Age-Related Macular Degeneration (Wet AMD) market share (%) distribution in 2022 and how it would look like in 2036?
• What would be the Wet Age-Related Macular Degeneration (Wet AMD) total market size as well as market size by therapies across the 7MM during the forecast period (2026-2036)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Wet Age-Related Macular Degeneration (Wet AMD) market size during the forecast period (2026-2036)?
• At what CAGR, the Wet Age-Related Macular Degeneration (Wet AMD) market is expected to grow at the 7MM level during the forecast period (2026-2036)?
• What would be the Wet Age-Related Macular Degeneration (Wet AMD) market outlook across the 7MM during the forecast period (2026-2036)?
• What would be the Wet Age-Related Macular Degeneration (Wet AMD) market growth till 2036 and what will be the resultant market size in the year 2036?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Wet Age-Related Macular Degeneration Epidemiology Insights

• What is the disease risk, burden, and unmet needs of Wet Age-Related Macular Degeneration (Wet AMD)?
• What is the historical Wet Age-Related Macular Degeneration (Wet AMD) patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient population of Wet Age-Related Macular Degeneration (Wet AMD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Wet Age-Related Macular Degeneration (Wet AMD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Wet Age-Related Macular Degeneration (Wet AMD) during the forecast period (2026-2036)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2026-2036)?

Current Wet Age-Related Macular Degeneration Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Wet Age-Related Macular Degeneration (Wet AMD) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Wet Age-Related Macular Degeneration (Wet AMD) in the US, Europe, And Japan?
• What are the Wet Age-Related Macular Degeneration (Wet AMD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Wet Age-Related Macular Degeneration (Wet AMD)?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Wet Age-Related Macular Degeneration (Wet AMD)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet AMD) therapies?
• What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet AMD) and their status?
• What are the key designations that have been granted for the emerging therapies for Wet Age-Related Macular Degeneration (Wet AMD)?
• What are the 7MM historical and forecasted market of Wet Age-Related Macular Degeneration (Wet AMD)?

Reasons to Buy Wet Age-Related Macular Degeneration Market Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Wet Age-Related Macular Degeneration (Wet AMD) Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1 Key Insights

2 Report Introduction

3 Wet AMD Market Overview at a Glance

• 3.1 Market Share (%) Distribution of Wet AMD by Therapies in 2022
• 3.2 Market Share (%) Distribution of Wet AMD by Therapies in 2036

4 Wet AMD Market: Future Perspective

5 Executive Summary

• 5.1 Wet AMD

6 Key Events

7 Disease Background and Overview

• 7.1 Introduction
  • 7.1.1 Classification and Clinical Manifestation
  • 7.1.2 Signs and Symptoms of AMD
  • 7.1.3 Risk Factors
  • 7.1.4 Pathophysiology of AMD
• 7.2 Diagnosis
• 7.3 Diagnostic Guidelines
  • 7.3.1 NICE Guidelines
  • 7.3.2 American Academy of Ophthalmology
  • 7.3.3 Harvard Ophthalmology
  • 7.3.4 European Society of Retina Specialists (EURETINA)
• 7.4 Treatment
• 7.5 Treatment Guidelines
  • 7.5.1 Harvard Ophthalmology
  • 7.5.2 American Academy of Ophthalmology
  • 7.5.3 European Society of Retina Specialists (EURETINA).

8 Epidemiology and Patient Population

• 8.1 Key Findings
• 8.2 Assumptions and Rationale: 7MM
  • 8.2.1 Prevalent Cases of AMD
  • 8.2.2 Diagnosed Prevalent Cases of AMD
  • 8.2.3 Type-specific cases of AMD
  • 8.2.4 Age-specific Cases of wet AMD
• 8.3 Total Prevalent Cases of AMD in the 7MM
• 8.4 Total Diagnosed Prevalent Cases of AMD in the 7MM
• 8.5 Total Diagnosed Prevalent Cases of Wet AMD in the 7MM
• 8.6 The United States
  • 8.6.1 Total Prevalent Cases of AMD in the US
  • 8.6.2 Total Diagnosed Prevalent Cases of AMD in the US
  • 8.6.3 Type-specific Diagnosed Prevalent Cases of AMD in the US
  • 8.6.4 Age-specific Diagnosed Prevalent Cases of Wet AMD in the US
• 8.7 EU4 and the UK
  • 8.7.1 Germany
    • 8.7.1.1 Total Prevalent Cases of AMD in Germany
    • 8.7.1.2 Total Diagnosed Prevalent Cases of AMD in Germany
    • 8.7.1.3 Type-specific Diagnosed Prevalent Cases of AMD in Germany
    • 8.7.1.4 Age-specific Diagnosed Prevalent Cases of Wet AMD in Germany
  • 8.7.2 France
    • 8.7.2.1 Total Prevalent Cases of AMD in France
    • 8.7.2.2 Total Diagnosed Prevalent Cases of AMD in France
    • 8.7.2.3 Type-specific Diagnosed Prevalent Cases of AMD in France
    • 8.7.2.4 Age-specific Diagnosed Prevalent Cases of Wet AMD in France
  • 8.7.3 Italy
    • 8.7.3.1 Total Prevalent Cases of AMD in Italy
    • 8.7.3.2 Total Diagnosed Prevalent Cases of AMD in Italy
    • 8.7.3.3 Type-specific Diagnosed Prevalent Cases of AMD in Italy
    • 8.7.3.4 Age-specific Diagnosed Prevalent Cases of Wet AMD in Italy
  • 8.7.4 Spain
    • 8.7.4.1 Total Prevalent Cases of AMD in Spain
    • 8.7.4.2 Total Diagnosed Prevalent Cases of AMD in Spain
    • 8.7.4.3 Type-specific Diagnosed Prevalent Cases of AMD in Spain
    • 8.7.4.4 Age-specific Diagnosed Prevalent Cases of Wet AMD in Spain
  • 8.7.5 The United Kingdom
    • 8.7.5.1 Total Prevalent Cases of AMD in the UK
    • 8.7.5.2 Total Diagnosed Prevalent Cases of AMD in the UK
    • 8.7.5.3 Type-specific Diagnosed Prevalent Cases of AMD in the UK
    • 8.7.5.4 Age-specific Diagnosed Prevalent Cases of Wet AMD in the UK
• 8.8 Japan
  • 8.8.1 Total Prevalent Cases of AMD in Japan
  • 8.8.2 Total Diagnosed Prevalent Cases of AMD in Japan
  • 8.8.3 Type-specific Diagnosed Prevalent Cases of AMD in Japan
  • 8.8.4 Age-specific Diagnosed Prevalent Cases of Wet AMD in Japan

9 Patient Journey

10 Marketed Drugs

• 10.1 Marketed Drugs Keycross
• 10.2 BEOVU (brolucizumab): Novartis
  • 10.2.1 Product Description
  • 10.2.2 Other Development Activities
  • 10.2.3 Clinical Trials Information
  • 10.2.4 Safety and Efficacy
  • 10.2.5 Product Profile

11 Emerging Drugs of Wet AMD

• 11.1 Key Competitors
• 11.2 OPT-302: Opthea Limited
  • 11.2.1 Product Description
  • 11.2.2 Other Development Activities
  • 11.2.3 Clinical Trial Information
  • 11.2.4 Safety and Efficacy
  • 11.2.5 Analysts' Views
• 11.3 KSI-501: Kodiak Sciences Inc.
  • 11.3.1 Product Description
  • 11.3.2 Other Development Activities
  • 11.3.3 Clinical Trial Information
  • 11.3.4 Safety and Efficacy
  • 11.3.5 Analysts' Views
• 11.4 RGX-314: REGENXBIO
  • 11.4.1 Product Description
  • 11.4.2 Other Development Activities
  • 11.4.3 Clinical Trial Information
  • 11.4.4 Safety and Efficacy
  • 11.4.5 Analysts' Views

12 Wet AMD: Market Analysis

• 12.1 Key Findings
• 12.2 Key Market Forecast Assumptions
• 12.3 Market Outlook
• 12.4 Conjoint Analysis
• 12.5 Total Market Size of Wet AMD in the 7MM
• 12.7 Market Size of Wet AMD by Therapies in the 7MM
• 12.7 Market Size of Wet AMD in the US
  • 12.7.1 Market size of Wet AMD
  • 12.7.2 Market size of Wet AMD by therapies
• 12.8 Market Size of Wet AMD in EU4 and the UK
  • 12.8.1 Market Size of Wet AMD in Germany
    • 12.8.1.1 Market size of Wet AMD
    • 12.8.1.2 Market size of Wet AMD by therapies
  • 12.8.2 Market Size of Wet AMD in France
    • 12.8.2.1 Market size of Wet AMD
    • 12.8.2.2 Market size of Wet AMD by therapies
  • 12.8.3 Market Size of Wet AMD in Italy
    • 12.8.3.1 Market size of Wet AMD
    • 12.8.3.2 Market size of Wet AMD by therapies
  • 12.8.4 Market Size of Wet AMD in Spain
    • 12.8.4.1 Market size of Wet AMD
    • 12.8.4.2 Market size of Wet AMD by therapies
  • 12.8.5 Market Size of Wet AMD in the UK
    • 12.8.5.1 Market size of Wet AMD
    • 12.8.5.2 Market size of Wet AMD by therapies
• 12.9 Market Size of Wet AMD in Japan
  • 12.9.1 Market size of Wet AMD
  • 12.9.2 Market size of Wet AMD by therapies

13 Key Opinion Leaders' Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

• 16.1 The United States
  • 16.1.1 Centre for Medicare and Medicaid Services (CMS)
• 16.2 In EU4 and the UK
  • 16.2.1 Germany
  • 16.2.2 France
  • 16.2.3 Italy
  • 16.2.4 Spain
  • 16.2.5 The United Kingdom
• 16.3 Japan
  • 16.3.1 MHLW

17 Appendix

• 17.1 Bibliography
• 17.2 Acronyms and Abbreviations
• 17.3 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer